|
[1]
|
Ferlay, J., et al. (2021) Cancer Statistics for the Year 2020: An Overview. International Journal of Cancer, 149, 778-789. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Zhang, J., Yang, P.L. and Gray, N.S. (2009) Targeting Cancer with Small Molecule Kinase Inhibitors. Nature Reviews Cancer, 9, 28-39. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Müller, S., Chaikuad, A., Gray, N.S. and Knapp, S. (2015) The Ins and Outs of Selective Kinase Inhibitor Development. Nature Chemical Biology, 11, 818-821. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Chen, P., et al. (2016) Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Molecular Cancer Therapeutics, 15, 2273-2281. [Google Scholar] [CrossRef]
|
|
[5]
|
O’Leary, B., Finn, R.S. and Turner, N.C. (2016) Treating Cancer with Selective CDK4/6 Inhibitors. Nature Reviews Clinical Oncology, 13, 417-430. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Finn, R.S., et al. (2020) Biomarker Analyses of Response to Cy-clin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. Clinical Cancer Research, 26, 110-121. [Google Scholar] [CrossRef]
|
|
[7]
|
Eggersmann, T.K., Degenhardt, T., Gluz, O., Wuerstlein, R. and Harbeck, N. (2019) CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib. BioDrugs, 33, 125-135. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Zhu, L., et al. (2022) Novel Therapeutic Strategy for Melanoma Based on Albendazole and the CDK4/6 Inhibitor Palbociclib. Scientific Reports, 12, Article No. 5706. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Roskoski Jr., R. (2022) Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors: A 2022 Update. Pharmacological Research, 175, Article ID: 106037. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Yuan, K., et al. (2021) Selective Inhibition of CDK4/6: A Safe and Effective Strategy for Developing Anticancer Drugs. Acta Pharmaceutica Sinica B, 11, 30-54. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Guarducci, C., et al. (2017) Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. Breast Care, 12, 304-308. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Veber, D.F., et al. (2002) Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. Journal of Medicinal Chemistry, 45, 2615-2623. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (2001) Ex-perimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Advanced Drug Delivery Reviews, 46, 3-26. [Google Scholar] [CrossRef]
|
|
[14]
|
Lätti, S., Niinivehmas, S. and Pentikäinen, O.T. (2016) Rocker: Open Source, Easy-to-Use Tool for AUC and Enrichment Calculations and ROC Visualization. Journal of Cheminformatics, 8, 45. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
夏侯真如, 薛孟祺, 汪欣怡, 等. 基于分子对接及药效团模型的木姜子属木脂素类化合物5-LOX抑制剂筛选研究(I) [J]. 云南大学学报(自然科学版), 2022, 44(2): 369-379.
|
|
[16]
|
Hutter, M.C. (2022) Differential Multimolecule Fingerprint for Similarity Search-Making Use of Active and Inactive Compound Sets in Virtual Screening. Journal of Chemical Information and Modeling, 62, 2726-2736. [Google Scholar] [CrossRef] [PubMed]
|